Neuroprotection & Alzheimer's Prevention Protocol
Four-compound Alzheimer's prevention stack targeting GSK-3β (Lithium Orotate), neuroinflammation (Omega-3 DHA), NGF/BDNF stimulation (Lion's Mane), and synaptic density (Magnesium Threonate) — for individuals with genetic risk or cognitive decline concerns.
Daily Schedule
Timing and dosage for each step
Evening
With meals
Morning
Evening
Protocol Overview
Alzheimer's disease pathology begins 15–20 years before clinical symptoms. The amyloid plaques and tau tangles observed in Alzheimer's brains accumulate over decades — meaning the window for prevention is in midlife, not when symptoms appear.
This protocol addresses four of the core Alzheimer's pathological mechanisms: GSK-3β-driven tau hyperphosphorylation (the direct cause of neurofibrillary tangles), neuroinflammation (the amplifier that accelerates neurodegeneration), NGF/BDNF depletion (the loss of neurotrophic support), and synaptic density decline (the earliest functional correlate of cognitive impairment).
Understanding Alzheimer's Risk
APOE4 carriers face 3–4x elevated Alzheimer's risk (one allele) or 8–12x (two alleles). Approximately 25% of the population carries at least one APOE4 allele. For APOE4 carriers specifically, early neuroprotective intervention has the strongest rationale.
Risk factors modifiable by this protocol: neuroinflammation, impaired synaptic function, reduced neurotrophic support, tau phosphorylation, and mitochondrial dysfunction.
The Four-Mechanism Approach
Lithium Orotate (5–10mg/day) — at microdose, lithium is a GSK-3β inhibitor. GSK-3β phosphorylates tau at multiple sites, creating the neurofibrillary tangles of Alzheimer's. Population epidemiology is remarkably consistent: regions with higher lithium in drinking water have statistically lower Alzheimer's rates and suicide rates. Nunes et al. (2013) demonstrated that even trace lithium levels in water correlate with reduced dementia mortality. This is the strongest mechanistic rationale for primary prevention.
Omega-3 DHA (2–3g EPA+DHA/day) — DHA is the primary structural fatty acid of neuronal membranes. Low DHA status is consistently associated with Alzheimer's risk in epidemiological studies. DHA-derived neuroprotectins (particularly neuroprotectin D1) inhibit amyloid-β-induced neuronal apoptosis and reduce microglial inflammatory activation — two of the core pathological mechanisms in Alzheimer's.
Lion's Mane (1,000mg/day) — stimulates NGF (nerve growth factor) production via hericenones and erinacines. NGF is required for the survival and maintenance of cholinergic neurons — the population that selectively dies in Alzheimer's disease. Supporting NGF production is among the most direct interventions available for Alzheimer's prevention.
Magnesium Threonate (1,500–2,000mg/day) — raises brain magnesium, which increases synaptic density. Synaptic loss is the earliest and most direct correlate of cognitive decline in Alzheimer's — preceding amyloid deposition in some models. Maintaining synaptic density through midlife provides cognitive reserve against Alzheimer's pathology.
Dosing Protocol
| Compound | Dose | Timing | Notes |
|---|---|---|---|
| Lithium Orotate | 5–10mg | Evening | Start at 5mg; increase to 10mg after 4 weeks |
| Omega-3 DHA | 2–3g EPA+DHA | With fatty meal | Triglyceride form; IFOS certified |
| Lion's Mane | 1,000mg | Morning | 8:1 extract minimum |
| Magnesium Threonate | 1,500–2,000mg | Evening (split) | 1,000mg at dinner, 500mg at bedtime |
Timeline of Effects
Weeks 1–4: Improved sleep quality (Magnesium Threonate), reduced brain fog. Weeks 4–12: Enhanced working memory (Magnesium Threonate), reduced anxiety (Lithium Orotate). Months 3–6: Neurogenesis benefits from Lion's Mane accumulate. NGF-mediated effects are slow but durable. Years 1+: Neuroprotective effects of Lithium Orotate (tau) and Omega-3 DHA (neuroinflammation) operate on timescales relevant to Alzheimer's prevention.
Who Should Consider This Protocol
Individuals aged 35+ with APOE4 carrier status, strong family history of Alzheimer's, subjective cognitive decline concerns, or any of: chronic neuroinflammation markers (elevated hs-CRP), omega-3 deficiency, or early memory concerns.
Monitoring
Annual: MoCA (Montreal Cognitive Assessment) score, omega-3 index (target >8%), homocysteine (elevated homocysteine is an independent Alzheimer's risk factor and is corrected by B12/folate, not this stack).